Nephrology Times

Nephrology Times The latest news in nephrological treatments and technologies

🎇 Have you heard? The NCQA has awarded its Population Health Program Accreditation to the Interwell 360 program.
12/17/2024

🎇 Have you heard? The NCQA has awarded its Population Health Program Accreditation to the Interwell 360 program.

The NCQA awarded Interwell Health a Population Health Program Accreditation for its Interwell 360 care management program for people living with chronic kidney disease (CKD).

The study examined whether is more effective than fluid restriction combined with furosemide and sodium chloride table...
12/17/2024

The study examined whether is more effective than fluid restriction combined with furosemide and sodium chloride tablets for patients with SIAD likely to fail with fluid restriction alone.

Tolvaptan increased serum sodium concentration without causing sodium overcorrection in syndrome of inappropriate antidiuresis.

Is there an association between hyperglycemic crises occurring at the time of diabetes diagnosis and a higher risk of de...
12/16/2024

Is there an association between hyperglycemic crises occurring at the time of diabetes diagnosis and a higher risk of developing CKD?

A study examined a possible association between hyperglycemic crises at diabetes diagnosis and a higher risk of developing chronic kidney disease (CKD).

The STOP Gout trial compared the efficacy and safety of allopurinol and febuxostat in the management of patients with go...
12/16/2024

The STOP Gout trial compared the efficacy and safety of allopurinol and febuxostat in the management of patients with gout using a treat-to-target approach.

Researchers evaluated the efficacy and safety of allopurinol versus febuxostat for gout management in patients with stage 3 chronic kidney disease (CKD).

The researchers examined physician confidence and barriers to prescription of for the management of .
12/15/2024

The researchers examined physician confidence and barriers to prescription of for the management of .

A study examined physician confidence and barriers to prescription of tolvaptan for the management of autosomal dominant polycystic kidney disease (ADPKD).

The researchers identified six candidate loci that were significantly associated with prognosis.
12/15/2024

The researchers identified six candidate loci that were significantly associated with prognosis.

Researchers identified six candidate loci that were significantly associated with IgA nephropathy prognosis, which could help define the molecular mechanisms of IgAN progression.

The study was the largest SnRNA-Seq profiling of IgAN kidney cells to date.
12/14/2024

The study was the largest SnRNA-Seq profiling of IgAN kidney cells to date.

The largest SnRNA-Seq profiling of IgAN kidney cells to date identified noteworthy cell-specific pathways in IgA nephropathy.

The study used bidirectional Mendelian randomization to examine causality between inflammatory skin diseases and . ...
12/14/2024

The study used bidirectional Mendelian randomization to examine causality between inflammatory skin diseases and .

A study examined a possible link between IgA nephropathy (IgAN) and inflammatory skin diseases, such as atopic dermatitis, acne, and psoriasis.

Loin pain is common among patients with IgAN but little is reported about its impact on quality of life or management st...
12/13/2024

Loin pain is common among patients with IgAN but little is reported about its impact on quality of life or management strategies.

A study examined the impact loin pain has on IgA nephropathy (IgAN) patients' quality of life and strategies to manage the pain.

European Medicines Agency clears the way for Ozempic's label to list a kidney disease indication.https://buff.ly/4fjah4b...
12/13/2024

European Medicines Agency clears the way for Ozempic's label to list a kidney disease indication.
https://buff.ly/4fjah4b

The European label for Ozempic will be updated to include an indication for risk reduction for events related to kidney disease.

New research addressed the lack of data on the association of blood pressure with post-AKI outcomes and the degree to wh...
12/13/2024

New research addressed the lack of data on the association of blood pressure with post-AKI outcomes and the degree to which time from discharge is associated with risks and benefits.

A study examined the associations of systolic blood pressure with mortality and hospital readmission post-acute kidney injury (AKI).

Post-trial follow-up of EMPA-KIDNEY gave a more complete measurement of the total effects of 2 years of in .
12/12/2024

Post-trial follow-up of EMPA-KIDNEY gave a more complete measurement of the total effects of 2 years of in .

In post-trial follow-up of EMPA-KIDNEY, benefits of empagliflozin continued for a period after discontinuation but were lesser and seemed temporary.

Research presented at examined the association between circulating inflammatory proteins and disease progression in ....
12/12/2024

Research presented at examined the association between circulating inflammatory proteins and disease progression in .

A study examined the association between circulating inflammatory proteins and disease progression in IgA nephropathy (IgAN).

The study assessed the efficacy and safety of BTK inhibitor in patients with primary membranous nephropathy.
12/11/2024

The study assessed the efficacy and safety of BTK inhibitor in patients with primary membranous nephropathy.

Bruton tyrosine kinase inhibitor zanubrutinib was found to be well tolerated and showed activity in patients with primary membranous nephropathy.

A subanalysis of FLOW data examined the effect of on mortality in patients with type 2 and .
12/11/2024

A subanalysis of FLOW data examined the effect of on mortality in patients with type 2 and .

Semaglutide reduced the risk of death, including cardiovascular death, among patients in the FLOW trial, who had chronic kidney disease (CKD) and type 2 diabetes.

Researchers determined that should be considered as an alternative therapy for refractory in cirrhosis.
12/10/2024

Researchers determined that should be considered as an alternative therapy for refractory in cirrhosis.

Contrary to recommendations, low-dose tolvaptan may be an option for refractory hyponatremia in cirrhosis.

ICYMI: Researchers shared results from a phase 3 trial of the acellular tissue engineered vessel in arteriovenous access...
12/10/2024

ICYMI: Researchers shared results from a phase 3 trial of the acellular tissue engineered vessel in arteriovenous access for patients with end-stage renal disease.

A trial found that an acellular tissue engineered vessel (ATEV) had better functional patency and usability compared to autologous arteriovenous fistula (AVF) for hemodialysis.

In rare cases, hypercalcemia may be caused by granulomatous inflammation associated with severe tophaceous gout.
12/09/2024

In rare cases, hypercalcemia may be caused by granulomatous inflammation associated with severe tophaceous gout.

Elevated 1,25-dihydroxyvitamin D in the setting of hypercalcemia as seen in a patient with severe tophaceous gout suggests abnormal unregulated extrarenal conversion.

Address

Manalapan, NJ
07726

Website

Alerts

Be the first to know and let us send you an email when Nephrology Times posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Nephrology Times:

Shortcuts

Share

Category